Owens & Minor Stock Price, News & Analysis

Owens & Minor (NYSE: OMI) will release third-quarter 2025 financial results on Thursday, October 30, 2025, after the New York Stock Exchange closes. The company will host a conference call for investors and analysts the same day at 5:00 p.m. EDT.

Dial-in numbers: toll-free 1-888-300-2035 and toll 1-646-517-7437 with conference ID 1058917. A simultaneous live webcast and a replay will be available on Owens & Minor's Investor Relations events page at investors.owens-minor.com/events-and-presentations/. Owens & Minor is a Fortune 500 healthcare solutions company serving hospital-to-home care with brands Apria, Byram, and HALYARD and about 20,000 teammates worldwide.

Platinum Equity announced a definitive agreement to acquire the Products & Healthcare Services (P&HS) segment from Owens & Minor (NYSE: OMI) on Oct. 7, 2025. Owens & Minor will retain a 5% equity stake in the standalone P&HS business. Headquartered in Richmond, VA, P&HS is a national distributor serving acute care hospitals and health systems. The transaction is expected to close near the end of 2025, subject to regulatory review and customary closing conditions. Platinum Equity reports approximately $50 billion AUM and a ~60-company operating portfolio, positioning it to pursue a carve-out and operational transformation of P&HS.

Owens & Minor (NYSE: OMI) entered a definitive agreement to sell its Products & Healthcare Services (P&HS) segment to Platinum Equity for $375 million cash at closing and will retain a 5% equity stake plus a preferred equity return tied to any future divestiture proceeds. The company will keep specified tax attributes exceeding $150 million. The deal preserves customer continuity and positions Owens & Minor as a pure‑play home‑based care platform. The transaction is subject to customary closing conditions, including Hart‑Scott‑Rodino and other regulatory approvals, and is expected to close near year‑end 2025.

Owens & Minor's (NYSE:OMI) subsidiaries Apria Healthcare and Byram Healthcare have secured a significant national provider agreement with Optum Health, effective September 1, 2025. The partnership integrates with Optum Health's network of 136,000 aligned care delivery physicians and 1,900 clinical sites.

As preferred DME network providers, Apria and Byram will offer a comprehensive range of durable medical equipment products for chronic and acute health needs, including diabetes, sleep health, respiratory care, wound care, urology, and ostomy care. The agreement aims to enhance patient care delivery and streamline the management of medical equipment needs for home-based care.

Owens & Minor (NYSE:OMI) reported Q2 2025 financial results, highlighting a significant strategic shift as it classifies its Products & Healthcare Services segment as discontinued operations due to an impending sale. The company's continuing operations, focused on Patient Direct, showed positive performance with revenue increasing to $681.9 million from $660.4 million year-over-year.

Q2 2025 results showed a GAAP loss from continuing operations of $(83.8) million, compared to $(6.7) million in Q2 2024. However, adjusted net income from continuing operations improved to $20.5 million versus $19.3 million year-over-year. Adjusted EBITDA grew to $96.6 million from $91.1 million in the prior year.

The company is transitioning to become a pure-play Patient Direct business, building on eight years of experience in this space, supported by favorable demographic trends and meaningful scale.

[ "Revenue growth to $681.9M in Q2 2025, up from $660.4M in Q2 2024", "Adjusted EBITDA increased to $96.6M from $91.1M year-over-year", "Adjusted net income from continuing operations improved to $20.5M from $19.3M", "Strategic focus on Patient Direct segment with favorable demographic trends" ]

Owens & Minor (NYSE: OMI), a Fortune 500 global healthcare solutions company, has scheduled its second quarter 2025 financial results release for Monday, August 11, 2025, before NYSE trading begins. The company will host a conference call at 8:30 a.m. EDT the same day.

Participants can join via toll-free number (1-888-300-2035) or toll number (1-646-517-7437) using conference ID 1058917. A live webcast will be available on the company's Investor Relations page, with a replay accessible after the presentation.

Owens & Minor (NYSE: OMI) announced the mutual termination of its previously announced acquisition of Rotech Healthcare Holdings. Under the agreement terms, OMI will pay Rotech $80 million and redeem $1 billion in notes issued in April 2025. The company cited regulatory challenges with the Federal Trade Commission as the main reason for termination, stating the merger clearance path proved unviable in terms of time, expense, and opportunity. OMI remains focused on growing its Patient Direct business and strengthening its balance sheet through improved cash flow generation for deleveraging. The company also disclosed ongoing discussions with interested parties regarding the potential sale of its Products and Healthcare Services business while continuing efforts to strengthen that segment.

Owens & Minor (NYSE: OMI) reported Q1 2025 financial results with revenue of $2.63 billion, a slight increase from $2.61 billion in Q1 2024. The company posted a GAAP net loss of $25.0 million ($0.32 per share), compared to a loss of $21.9 million ($0.29 per share) in Q1 2024. Patient Direct segment showed strong performance with mid-single digit top-line growth and 173 basis points operating margin expansion. The company reaffirmed its 2025 guidance, projecting revenue of $10.85-11.15 billion and adjusted EBITDA of $560-590 million. Management remains actively engaged in the potential sale of the Products & Healthcare Services segment and continues to work on integrating the planned Rotech acquisition.